Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03872141 · ClinicalTrials.gov registry record
Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 13
- Enrollment target
NCT03872141 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 13 participants.
The verdict
NCT03872141 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The purpose of this prospective, non-interventional study is to perform neurological and cognitive assessment of breast cancer patients who receive standard of care single agent weekly paclitaxel docetaxel chemotherapy to determine the onset and severity of chemotherapy induced neuropathy (CIPN) and cognitive impairment (CICI).
Interventions
- DIAGNOSTIC_TEST Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-05-23 |
| Est. Completion | 2021-02-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03872141
The ClinicalTrials.gov registry entry for NCT03872141 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer is the first listed.
NCT03872141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03872141 about?
NCT03872141 is a clinical study titled "Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients". The purpose of this prospective, non-interventional study is to perform neurological and cognitive assessment of breast cancer patients who receive standard of care single agent weekly paclitaxel docetaxel chemotherapy to determine the onset and severity of chemotherapy induced neuropathy (CIPN) and...
What is the current status of trial NCT03872141?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2017-05-23. Estimated completion is 2021-02-25.
What interventions are being tested in trial NCT03872141?
The interventions under investigation include: Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03872141?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.